Related Experiment Video
Updated: Jun 4, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
MDM2 and MDMX in cancer and development
1VIB–K.U.Leuven, Department of Molecular and Developmental Genetics, Laboratory for Molecular Cancer Biology, Leuven, Belgium.
The p53 tumor suppressor pathway is normally activated by cellular stress but is often silenced in cancer cells. Tumor cells hijack normal mechanisms, like MDM2 and MDMX proteins, to inhibit p53, offering potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Biology
Background:
- The p53 tumor suppressor pathway is crucial for cellular response to stress and DNA damage, inducing cell cycle arrest or apoptosis.
- In normal, unstressed cells and in most tumor cells, p53 activity is tightly regulated or silenced.
- p53 inactivation in tumors occurs via mutations or other mechanisms affecting its function.
Purpose of the Study:
- To explore how tumor cells inactivate the p53 pathway.
- To investigate the role of MDM2 and MDMX proteins in p53 regulation within tumor cells.
- To discuss the implications for novel cancer therapeutic strategies.
Main Methods:
- Review of recent biochemical and genetic data.
- Analysis of aberrant protein expression in tumor cells.
- Examination of mechanisms restraining p53 function.
Main Results:
- Tumor cells utilize mechanisms normally employed to restrain p53.
- Aberrant expression of MDM2 and MDMX proteins is observed in tumor cells.
- These proteins play a key role in maintaining p53 in an inactive state.
Conclusions:
- Tumor cells actively suppress p53 function by co-opting normal regulatory pathways.
- MDM2 and MDMX are critical in enforcing p53 silencing in cancer.
- Understanding these mechanisms provides a basis for developing new anti-cancer therapies targeting the p53 pathway.
Related Concept Videos
Abnormal Proliferation
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Epigenetic Regulation
Mitogens and the Cell Cycle
Positive Regulator Molecules
